To date, five coronavirus disease 2019 (COVID-19) vaccines have been conditionally approved for market authorization or granted emergency use authorization in China by the National Medical Products Administration (NMPA).

Based on clinical trial data of the NMPA-approved domestic vaccines and the epidemiological characteristics of COVID-19, the COVID-19 Vaccine Technical Working Group of China CDC drafted technical vaccination recommendations which the National Immunization Advisory Committee (NIAC) have reviewed, discussed, and refined.

These recommendations are approved by the National Health Commission and can be used by health departments and disease control institutions at all levels in China to guide COVID-19 vaccination.

This is the first edition, which will be updated as needed.

Recommendation South-East Asia China COVID-19